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Low dose of protein A pretreatment can alleviate the inflammatory reaction
and the bio-safety was evaluated in vivo
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Received July 9, 2015; accepted November 27, 2015AbstractBackground: Staphylococcal protein A (SPA) is a protein of Staphylococcus aureus. Up to now, there have been many studies on the biological
activities of SPA. Some reported effects of SPA pretreatment on septic shock in mouse models but there is no study which reports the role of SPA
pretreatment on the infected incision.
Methods: According to count results, bacterial suspension was set at a density of ~1.8  109 colony forming units/mL. BALB/c mice were
anesthetized via intraperitoneal injection with pentobarbital sodium. A longitudinal skin incision was made on the medial side of the right thigh.
The length of the incision was 5 mm, and the depth was ~3 mm. The bacterial suspension was gradually dripped and embrocated onto the
incision surface to make the wound infection model. Before making the wound infection model for 48 hours and 24 hours, mice were retreated
with SPA via intraperitoneal injection. Rats were intraperitoneally injected with SPA 1 mg/kg and the control group was injected with sterile
saline to evaluate the biological safety of the best pretreatment dose.
Results: A 1-mL bacterial suspension can be utilized to make the wound infection model of BALB/c mouse lower limb. SPA pretreatment can
reduce the inflammatory reactions in wound methicillin-resistant Staphylococcus aureus infection mouse model and the best pretreatment dose is
1 mg/kg. Intraperitoneal injection 1 mg/kg SPA does not destroy the functions of the organs. A 1-mg/kg SPA pretreatment can also reduce the
inflammatory reactions in wound various bacterial infection mouse models.
Conclusion: SPA pretreatment can effectively decrease the infected severity of a wound infected by various bacteria in a BALB/c mouse model.
The best pretreatment dose is 1 mg/kg, and this dose does not damage organ function in rats up to a point.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Staphylococcal protein A (SPA) is a protein in Staphylo-
coccus aureus.1e3 It can form precipitation with highly diluted
immune sera from an animal inoculated with S. aureus or SPA.4
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SPA, whereas few species of coagulase-negative S. aureus have
SPA.5,6 Low doses of SPA can cause an allergic reaction and high
doses can cause bleeding and arthus reaction.7However, SPA can
activate the complement. When the body is infected with S.
aureus, SPA can combinewith IgG to activate the complement to
localize the infection.4,8,9 SPA has further important capabilities,
including: (1) inhibiting the phagocytosis of macrophages;10 (2)
activating B cells with T cells;11,12 and (3) inducing B cells to
synthesize and secrete polygonal antibody.11 As an immuno-
modulator, a low dose SPA pretreatment can adjust the body
immune system response. When the body is infected after SPA
pretreatment, the body can therefore respondquickly.Alongwith
the study of the effects of SPA on the immune system, somesevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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from a lethal infection of S. aureus.13 However, no published
research currently exists regarding SPA pretreatment on the
infected incision. Our study is based on a BALB/c mice infected
incision model, exploring SPA pretreatment with different doses
on an incision infected by methicillin-resistant S. aureus
(MRSA), assessing the bio-safety of the best pretreatment dose,
and analyzing the effects of SPA pretreatment on the incision
infected by different bacteria.
2. Methods2.1. BacteriaMethicillin-sensitive S. aureus (MSSA) strain ATCC 25923,
MRSA strain ATCC 33591, Pseudomonas aeruginosa strain
ATCC 27853, and Escherichia coli strain ATCC 25922 were all
from American Type Culture Collection (Manassas, VA, USA).2.2. Mice and ratsFig. 1. The temperature variation in different pretreated groups of MRSA
infected mice. Cut ¼ incision only; MRSA ¼ methicillin-resistant Staphylo-
coccus aureus; saline ¼ sterile saline pretreatment; SPA ¼ staphylococcal
protein A; SPA 0.5 ¼ SPA 0.5 mg/kg pretreatment; SPA 1 ¼ SPA 1 mg/kg
pretreatment; SPA 1.5 ¼ SPA 1.5 mg/kg pretreatment; SPA 2 ¼ SPA 2 mg/kg
pretreatment.Adult BALB/c mice (20 g) and adult Wistar rats (200 g)
were obtained from the Charles River Laboratories (Beijing,
China). All procedures were performed in accordance with the
guiding principles in the Care and Use of Animals and
approved by the Capital Medical University Committee on the
Use of Animals in Research and Education. Animals were
separately housed in plastic cages in a room maintained at
23.6C and 35% humidity with 12-hour light/dark cycles (light
on at 07:00 AM). Each animal was used only once and fed a
standard chow diet with unrestricted water intake. Experi-
ments were conducted in an ABSL-2 laboratory and at the end
of the experiments, the animals were anesthetized using
pentobarbital sodium and then euthanized.2.3. ReagentsRecombinant SPA was from the Sino Biological Inc. in
Beijing China, product number: 10600-P07E. ELISA kits forTable 1
Day 4 of the observation results of the incision.
Slightly red
and swollen
Obviously red
and swollen
Appeared pus
MRSA 1 mL 5 7
MRSA 0.5 mL 8 4
MRSA 0.25 mL 4 7 1
MSSA 1 mL 9 3
MSSA 0.5 mL 10 2
MSSA 0.25 mL 6 6 0
P. aeruginosa 1 mL 7 5
P. aeruginosa 0.5 mL 9 3
P. aeruginosa 0.25 mL 2 8 2
E. coli 1 9 3
E. coli 0.5 mL 10 2
E. coli 0.25 mL 3 8 1
E. coli ¼ Escherichia coli; MRSA ¼ methicillin-resistant Staphylococcus
aureus; MSSA ¼ Methicillin-sensitive Staphylococcus aureus; P.
aeruginosa ¼ Pseudomonas aeruginosa.the detection of IL-1b, IL-6, IL-10, and TNF-a were from the
Dakewe Bioengineering Company in Beijing, China.2.4. Preparation of bacteria suspensionBacteria were cultured in Trypticase soy broth (Beijing,
China) which was conducted in an incubator at 37C in a 95%
humidified atmosphere and 5% CO2. Then, 0.2 mL bacterial
culture solution was diluted 1:10 into sterile saline (Biosntech
Company. Beijing, China) and measured the optical density
(OD) value at 600 nm of the diluted solution every 1 hour. The
growth of bacteria was in the exponential phase when the OD
value was rapidly increasing.14,15 Then, the bacteria were
segmented (4C, 6  103 r/min 15 min), washed, and sus-
pended in sterile saline. A 0.2-mL suspension was diluted
1:104 into sterile saline. To 0.2 mL of the diluted suspension
0.4 mL 0.4% trypsin blue solution was added and mixed well
to stain for 2 minutes. A 2-mL sample of the stained solution
was flowed into the cell counter. According to the count re-
sults, bacterial suspension was set at a density of
~1.8  109 CFU/mL.2.5. The incision infection modelBALB/c mice were randomly distributed into 13 groups,
and each group consisted of 12 male. Mice of the control
group received incisions made at the medial side of the right
thigh without bacteria suspension dripped onto the surface.
Fig. 3. Groups infected by MRSA. (A) Group A (SPA 0.5 mg/kg pretreatment) subcutaneous tissue was damaged and inflammatory cells infiltrated,  40; (B)
Group B (SPA 1 mg/kg pretreatment) epithelial tissue had healed and inflammatory response was milder,  40; (C) Group C (SPA 1.5 mg/kg pretreatment)
epithelial tissue did not heal and appeared subcutaneous abscess (arrow),  40; (D) Group D (SPA 2 mg/kg pretreatment) epithelial tissue did not heal and tissue
was damaged (arrow),  40; (E) Group E (sterile saline pretreatment) epithelial tissue did not heal and tissue was damaged,  40; (F) Group F (cut only) epithelial
tissue did not heal and appeared subcutaneous abscess (arrow),  40; (G) Group B in which splenic lymphoid nodules increased less (arrow in lymph
nodules),  40; and (H) Group E in which splenic lymphoid nodules increased much (arrow in lymph nodules),  40. MRSA ¼ methicillin-resistant Staphy-
lococcus aureus; SPA ¼ staphylococcal protein A.
Fig. 2. The temperature variation of mice. E. coli ¼ Escherichia coli; MSSA ¼ Methicillin-sensitive Staphylococcus aureus; P. aeruginosa ¼ Pseudomonas
aeruginosa; SPA ¼ staphylococcal protein A.
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Fig. 4. Groups infected by different bacteria with SPA 1 mg/kg pretreatment. (A) and (I) Group P (MSSA infected),  40; (B) and (J) Group Q (P. aeruginosa
infected),  40; (C) and (K) Group R (E. coli infected),  40; (D) Group R (E. coli infected),  40; (E) and (M) Group T (P. aeruginosa infected and sterile saline
pretreated),  40; (F) Group U (E. coli infected and sterile saline pretreated),  40; (G) and (N) Group W (P. aeruginosa infected only),  40; (H) and (O) Group
X (E. coli infected only),  40; and (L) Group S (MSSA infected and sterile saline pretreated),  40. E. coli ¼ Escherichia coli; MSSA ¼ Methicillin-sensitive
Staphylococcus aureus; P. aeruginosa ¼ Pseudomonas aeruginosa.
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Table 2
The white blood cells, granulocyte, lymphocytes, and cytokines in different MRSA infected pretreatment groups.
Day 3
Group A
SPA 0.5
Group B
SPA 1
Group C
SPA 1.5
Group D
SPA 2
Group E
Saline
Group F
Cut
White blood cells 12.5563 ± 0.64804 10.9562 ± 0.74114 11.6562 ± 0.72935 13.4750 ± 0.54345 14.0125 ± 0.96945 14.2813 ± 0.89608
Granulocyte 2.5062 ± 0.57904 2.0563 ± 0.43508 2.1813 ± 0.26133 2.8188 ± 0.53068 3.0375 ± 0.54757 3.3688 ± 0.58163
Lymphocytes 8.7875 ± 0.61847 7.3500 ± 0.53166 7.8250 ± 0.70380 9.7750 ± 0.92268 10.1875 ± 0.92727 10.4688 ± 0.76830
Days 7
Group A
SPA 0.5
Group B
SPA1
Group C
SPA1.5
Group D
SPA2
Group E
Saline
Group F
Cut
White blood cells 8.7000 ± 1.03923 7.5063 ± 0.87975 7.8438 ± 0.73391 9.3250 ± 0.77760 9.8813 ± 1.00546 10.3063 ± 0.66380
Granulocyte 1.7313 ± 0.34779 1.4313 ± 0.33807 1.6063 ± 0.40574 1.7750 ± 0.33166 1.8375 ± 0.43186 2.0500 ± 0.46043
Lymphocytes 6.2500 ± 0.57504 5.4688 ± 0.73368 5.7625 ± 0.88910 6.5500 ± 0.67132 7.0750 ± 0.51833 7.2438 ± 0.45456
IL-1b 221.1250 ± 19.32140 148.3750 ± 27.18793 182.3750 ± 34.98357 258.6875 ± 20.96893 292.2500 ± 32.77702 287.0000 ± 38.61261
IL-6 378.0625 ± 24.39254 287.9375 ± 37.34429 322.0000 ± 27.00617 451.6875 ± 20.19478 500.1250 ± 21.10253 493.6250 ± 25.44766
IL-10 142.0000 ± 18.51126 117.8125 ± 19.66119 129.1875 ± 20.43271 158.3750 ± 21.39120 182.3125 ± 19.71030 179.7500 ± 22.71123
TNF-a 156.1250 ± 18.72209 110.5625 ± 22.29490 121.9375 ± 20.65742 170.6250 ± 18.82507 208.6875 ± 29.16326 206.6875 ± 19.45154
Cut ¼ incision only; saline ¼ sterile saline pretreatment; MRSA ¼ methicillin-resistant Staphylococcus aureus; SPA ¼ staphylococcal protein A; SPA 0.5 ¼ SPA
0.5 mg/kg pretreatment; SPA 1 ¼ SPA 1 mg/kg pretreatment; SPA 1.5 ¼ SPA 1.5 mg/kg pretreatment; SPA2 ¼ SPA 2 mg/kg pretreatment.
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gradually dripped onto the surface of the incision and
embrocated with a sterile bacterial inoculation needle after
the incision was made.16 The volume of the bacteria sus-
pension used was 1 mL, 0.5 mL, or 0.25 mL at a concen-
tration with 1.8  109 CFU/mL. The length of the incision
was 5 mm and the depth was ~3 mm. We did not cut the deep
fascia, and the bacterial suspension did not overflow the
incision.2.6. SPA pretreatmentOnce again, the mice were randomly distributed into 20
groups and each group was 12 male. Mice of the control group
received incision infection without SPA pretreatment. Mice of
the other group received SPA intraperitoneally injected before
the incision infection was made. The dose of SPA used 0.5 mg/
kg/time, 1 mg/kg/time, 1.5 mg/kg/time, or 2 mg/kg/time. SPA
was injected at 48 hours and 24 hours before making the
incision infection model. A digital thermometer (Shenzhen
Life Technologies Corporation, Shenzhen, China) was used to
measure rectal temperature and was adjusted to rectal probe to
minimize the stress response 2e5 days before the experiment.
The mice were gently handled and removed from their cages
10 times daily for 20 minutes every time. The probe was
inserted 2 cm into the rectum. Each measurement value
recorded was a mean of six, and the temperature was measured
at 09:00 AM.2.7. Assess the biological safety of the best pretreatment
doseRats were randomly distributed into two groups, with each
group consisting of 20.5 male. Rats of the control group
received sterile saline intraperitoneally injected, and the other
group received 1 mg/kg SPA intraperitoneally injected.2.8. Statistical analysisAll data are expressed as means ± standard deviation (SD)
and results were subjected to statistical analysis using analysis
of variance (ANOVA) for repeated measurements or one-way
ANOVA. Values of p < 0.05 were considered significant.
3. Results3.1. The incision infection modelA 0.5-mL MSSA, MRSA, P. aeruginosa, or E. coli sus-
pension could make the incision red and swell. A 0.25-mL
suspension could not make the entire incision red. A 1-mL
suspension was difficult to control and not overflow the inci-
sion (Table 1). These results reproduced our previous findings
and suggest that 0.5 mL MSSA, MRSA, P. aeruginosa, or E.
coli bacteria suspension could produce a stable incision
infection model.3.2. SPA pretreatment on incision infection modelSPA pretreatment can effectively reduce the increased
amplitude of temperature, white blood cells, blood granulocyte,
blood lymphocytes, serum IL-1b, serum IL-6, serum IL-10, and
serum TNF-a in mice infected byMSSA,MRSA,P. aeruginosa,
or E. coli (Figs. 1e4 and Tables 2 and 3). A 1-mg/kg/time SPA
pretreatment could be more effective in reducing the increased
amplitude of these observation indicators than 0.5 mg/kg/time,
1.5 mg/kg/time, and 2 mg/kg/time in mice infected by MSSA,
MRSA, P. aeruginosa, or E. coli.3.3. Biological safety of the best pretreatment doseRat biochemistry included total cholesterol, calcium,
amylase, alanine aminotransferase, alkaline phosphatase, and
Table 3
The white blood cells, granulocyte, lymphocytes, and cytokines in different bacteria infected groups with SPA 1 mg/kg pretreated.
Day 3
MSSA þ SPA PA þ SPA EC þ SPA MSSA þ saline PA þ saline EC þ saline MSSA PA EC
White blood
cells
10.2191 ± 0.21797 11.8004 ± 0.22035 11.2981 ± 0.24156 12.6745 ± 0.24660 13.6032 ± 0.24468 13.0864 ± 0.24475 12.5376 ± 0.21537 13.6157 ± 0.26069 13.1286 ± 0.24875
Granulocyte 1.9922 ± 0.14485 2.2106 ± 0.18973 2.2228 ± 0.17093 2.8122 ± 0.15718 2.9449 ± 0.16502 2.9959 ± 0.20450 2.8421 ± 0.15303 2.9942 ± 0.14555 2.9524 ± 0.17386
Lymphocytes 7.1912 ± 0.26590 8.2479 ± 0.25238 7.8696 ± 0.23463 9.0899 ± 0.19316 10.0414 ± 0.18653 9.6121 ± 0.24427 9.0652 ± 0.27499 10.3832 ± 0.17816 9.6278 ± 0.22727
Day 7
MSSA þ SPA PA þ SPA EC þ SPA MSSA þ saline PA þ saline EC þ saline MSSA PA EC
White blood
cells
6.6067 ± 0.16970 7.6345 ± 0.25668 7.1835 ± 0.24213 8.8001 ± 0.15808 10.3037 ± 0.25359 9.7867 ± 0.24275 8.8459 ± 0.15846 10.2865 ± 0.25093 9.7165 ± 0.18148
Granulocyte 1.2082 ± 0.15758 1.4838 ± 0.17336 1.2884 ± 0.14809 1.3227 ± 0.16304 1.9957 ± 0.15813 1.6822 ± 0.17669 1.2816 ± 0.17807 1.9101 ± 0.15236 1.7225 ± 0.20574
Lymphocytes 4.9761 ± 0.19309 5.7694 ± 0.19355 5.3015 ± 0.25664 6.6257 ± 0.23478 7.7803 ± 0.21715 7.2210 ± 0.16063 6.7944 ± 0.24684 7.8927 ± 0.21611 7.2972 ± 0.23691
IL-1b 102.7607 ± 5.05716 196.4954 ± 7.20748 159.0481 ± 6.21894 206.0315 ± 4.43192 281.2292 ± 5.72820 252.7364 ± 6.12305 201.9237 ± 7.27873 278.8555 ± 7.23173 253.3289 ± 6.72381
IL-6 152.4182 ± 8.93504 308.0875 ± 6.54658 270.5582 ± 6.23574 349.8513 ± 6.09951 503.8268 ± 7.45727 449.7282 ± 7.33428 348.0479 ± 6.73888 499.4506 ± 5.46794 449.4989 ± 6.30244
IL-10 49.7535 ± 6.13059 100.2269 ± 5.93442 91.4796 ± 6.74735 120.1501 ± 7.10589 171.2849 ± 6.33269 149.7192 ± 6.79272 121.4941 ± 7.46950 170.5110 ± 6.25104 151.8955 ± 6.21908
TNF-a 52.4091 ± 3.05169 109.0857 ± 6.94824 88.0083 ± 5.81353 127.7865 ± 6.27617 198.8187 ± 6.68154 179.1827 ± 6.25702 128.9310 ± 5.97829 202.1593 ± 5.08195 181.6701 ± 7.00167
EC ¼ Escherichia coli infected only; EC þ SPA ¼ E. coli infected and SPA pretreated; E. coli þ saline ¼ E. coli infected and sterile saline pretreated; MSSA ¼ Methicillin-sensitive Staphylococcus aureus;
MSSA ¼ MSSA infected only; MSSA þ saline ¼ MSSA infected and sterile saline pretreated; MSSA þ SPA ¼ MSSA infected and SPA pretreated; PA¼ Pseudomonas aeruginosa infected only; P.
aeruginosa þ saline ¼ P. aeruginosa infected and sterile saline pretreated; PA þ SPA¼ P. aeruginosa infected and SPA pretreated; SPA ¼ staphylococcal protein A.
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Fig. 5. The temperature variation of rats. SPA ¼ staphylococcal protein A.
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transpeptidase, creatinine, glucose, phosphate and total bili-
rubin, total protein, and urea. A 1-mg/kg SPA pretreatment did
not cause these indicators to be abnormal.
A 1-mg/kg SPA pretreatment could increase the rat tem-
perature, white blood cells, blood granulocyte, blood lym-
phocytes, serum IL-1b, serum IL-6, serum IL-10, and serum
TNF-a, and these indicators returned to normal in 24 hours
(Figs. 5 and 6).
Liver tissues of rats pretreated by 1 mg/kg SPA were
observed under the microscope and there was no damaged
organizational structure.
In all the experiments, the position at which SPA was
injected did not appear to have signs of infection at any time.
4. Discussion
SPA is a surface protein on most S. aureus strains, and can
bind to various host-derived proteins, including the Fc and
VH3 domains of immunoglobulins, von Willebrand factor,
complement C3, epidermal growth factor receptor, and TNF-a
receptor 1. Thus, SPA can potentially modulate the host im-
mune system. Depending on its binding partner and respond-
ing cell type in a host, SPA can act as either a proinflammatory
or antiinflammatory molecule.
Surgical site infection (SSI) is a common complication
after surgery. It immediately influences the curative effect of
the operation. Bacteria will form a biofilm on the internal
fixation plate, which is utilized during most of the orthopedic
surgeries. The biofilm can resist the body immune system and
antibiotics.17,18 Ways to improve cleaning of the bacteria and
reduce the biofilm formed continues to be investigated. In
recent years, one study reported that SPA can enhance theability of the body's immune system to resist sepsis and reduce
mortality due to infection shock.6,7 However, the further mo-
lecular mechanism involved remains unresolved and continues
to generate discussion. In our study we assessed the SPA
pretreatment on the incision infection mouse model and
selected the best pretreatment dose. On the one hand, we
explored the possibility that SPA can alleviate the inflamma-
tion of incision infection mouse to possibly reduce SSI; on the
other hand, we undertook a further study to find the exact
mechanism of SPA on the body immune system to provide a
hypothesis.
The medial soft tissue of the thigh was thicker compared
with the other site that was considered, and the local
anatomical structure was clear. The incision which we chose
can make the incision infection model easily established and
standard. Bacteria suspension can be flowed via the space
between the muscles to diffuse if the fascia was cut. How-
ever, we did not cut the fascia to make the bacteria only
infect the incision surface, and not diffuse the other site.
Under clinical conditions, the source of bacteria of SSI is
customarily from the air. Essentially, the bacteria drops onto
the incision surface which initiates the SSI process. There-
fore, our goal was to simulate that manner of infection.
In our experiment, a low dose of SPA can alleviate inflam-
mation by detecting the body's temperature, white blood cells,
granulocyte, lymphocyte, serum cytokines, and wound tissue
biopsy. Once bacteria invade, the immune response was rapidly
activated, and lymphocytes rapidly proliferate and differentiate.
Soon thereafter, the bacteria will be cleared quickly.
We found that 1 mg/kg/time SPA pretreatment has the best
protection effect compared with the other doses. This indicates
that the spectrum of treatment of SPA is narrow, in part because
SPA is toxic to the body. Overall, the SPA treatment mechanism
Fig. 6. The variation of lL-1b, lL-6, lL-10, and TNF-a. SPA ¼ staphylococcal protein A.
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can activate some receptors. The activation effects have a dose
dependent relationship. The dose below the threshold value may
fail to activate the immune system and be clear. Alternatively, the
dose that exceeds the threshold value could cause harm. How-
ever, this hypothesis needs to be proven by further research.In conclusion, the findings of this study suggest that SPA
pretreatment can effectively reduce the severity of the infected
incision of MRSA, MSSA, P. aeruginosa, or E. coli infection.
The best dose of SPA pretreatment is 1 mg/kg, which is a
dosage that, up to a point, does not damage the function of the
organs in Wistar rats.
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